Navigation Links
Pharmaceutical Direct to Consumer Advertising on The American Law Journal
Date:1/17/2010

PHILADELPHIA, Jan. 17 /PRNewswire/ -- In the last decade, the number of consumers taking antidepressants has more than doubled, with a staggering 4000% increase in the diagnosis of bipolar disorder in children in that time.  Doctors wrote 164 million prescriptions for antidepressants in 2008. Pharmaceutical companies spend billions of dollars on direct to consumer pharmaceutical advertising psychiatric drugs. Is there a connection? And when a patient experiences harm from a drug, does direct to consumer advertising play a role in litigation?

Monday January 18 live from 7:00-8:00 p.m. EST on the Philadelphia CNN-News affiliate WFMZ-TV and streaming online at WFMZ.com, The American Law Journal presents "Ask Your Doctor If 'x' is Right for You— Does Drug Advertising Help or Hurt the Consumer?" Philadelphia-based lawyers and a prominent pain physician address the legal, medical and social implications of direct to consumer drug advertising. Former New Jersey prosecutor Christopher Naughton, a legal commentator and 20-year legal broadcasting veteran, hosts the program.

On the panel representing consumers and pharmaceutical whistleblowers in nationwide, complex pharmaceutical litigation and recent landmark pharmaceutical settlements is Stephen Sheller, Esq. of the law firm of Sheller, P.C.. Raymond Williams, Esq. of DLA Piper brings his expertise defending top-tier pharmaceutical companies in high-profile cases to the conversation. Joining Sheller and Williams is physician Frank J.E. Falco, M.D., CEO of the Mid-Atlantic Spine & Pain Physicians and Vice President of the American Society of Interventional Pain Physicians. The program will address both informational and product drug advertising with an emphasis on the rapid growth of marketing and prescribing antidepressant and antipsychotic drugs.

Despite health concerns and the increase in lawsuits involving antipsychotic drugs, "we're seeing more drug advertising with 'if you're antidepressant isn't doing enough for you' ads," says Sheller, "and with the FDA approving the use of antipsychotics in children, it's becoming a huge moral question."

The American Law Journal is a weekly talk-feature program that addresses consumer, business and constitutional law. The program is seen throughout the Philadelphia tri-state region, streams live, and is available for download. Free links for downloads are available by request from info@lawjournaltv.com while the program website is under renovation. Next week on The American Law Journal: "The Lawyer, the Client, the Insurance Adjuster & the Judge."

Available Topic Experts: For information on the listed expert(s), click appropriate link.

Christopher Naughton   |   https://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=85988

Stephen  Sheller, Esq.   |   https://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=85992

SOURCE The American Law Journal


'/>"/>
SOURCE The American Law Journal
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
7. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
8. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
9. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
10. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
11. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... A key trend that will ... of new treatments. Cardax, a development stage life sciences ... therapy is expected to fulfil large unmet medical needs ... studies to develop new treatments for osteoarthritis. One such ... in osteoarthritis are being investigated, and early trials of ...
(Date:5/25/2016)... FDA 510(k) clearance covers Confocal Miniprobes ... and surgical applications Mauna Kea Technologies ... multidisciplinary confocal laser endomicroscopy (CLE) platform, today announced ... the 12 th 510(k) clearance from United ... FDA clearance covers Confocal Miniprobes indicated for use ...
(Date:5/25/2016)...  Zymo Research Corp. announced today the final ... that help researchers obtain the most accurate and ... rapid growth of the study of microbiomes has ... methods to improve the reproducibility and quality of ... every step of the measurement process including collection ...
Breaking Medicine Technology:
(Date:5/27/2016)... ... May 27, 2016 , ... Two director-level employees of ... Tribute to Women and Industry (TWIN) 2016 honorees. The award recognizes businesswomen who ... this year, Geri Boone, Director of the MLTSS (Managed Long-Term Services and Supports) Program ...
(Date:5/27/2016)... ... 27, 2016 , ... This campaign aims to provide a path to improved ... can control and change. , As nearly 795,000 Americans suffering from a new or ... States. Plus, with an estimated 129,000 of these people dying from stroke, it’s become ...
(Date:5/27/2016)... ... May 27, 2016 , ... Aimed at nurses ... human interest stories, courtesy of leaders in the nursing and health care industry. ... from leading advocates and associations—namely Jones & Bartlett Learning. , Jones & Bartlett ...
(Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... Despite last ... meeting, expect Janet Yellen and company to wait until March 2017 for an interest ... University’s J. Mack Robinson College of Business. , “The Federal Open Market Committee (FOMC) ...
(Date:5/26/2016)... ... May 26, 2016 , ... ... hosted members and suppliers for its inaugural Member Conference at the Paris Hotel ... of elevating the operational health of America’s healthcare providers. , The conference was ...
Breaking Medicine News(10 mins):